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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an important differential diagnosis in heart failure
(HF). However, routine use of spirometry in outpatient HF clinics is not implemented. The aim of the present study
was to determine the prevalence of both airflow obstruction and non obstructive lung function impairment in
patients with HF and to examine the effect of optimal medical treatment for HF on lung function parameters.
Methods: Consecutive patients with HF (ejection fraction (EF) < 45%) and New York Heart Association (NYHA)
functional class II-IV at 10 different outpatient heart failure clinics were examined with spirometry at their first visit
and after optimal medical treatment for HF was achieved. airflow obstruction was classified and graded according
to the GOLD 2011 revision.
Results: Baseline spirometry was performed in 593 included patients and 71 (12%) had a clinical diagnosis of
COPD. Mean age was 69 ± 11 years and mean EF was 30 ± 9%. Thirty-two % of the patients were active smokers
and 53% were previous smokers. Mean FEV1 and FVC was 77.9 ± 1.7% and 85.4 ± 1.5% of predicted respectively.
Obstructive pattern was observed in 233 (39%) of the patients. Of these, 53 patients (9%) had mild disease (GOLD I)
and 180 (30%) patients had moderate to very severe disease (GOLD II-IV). No difference in spirometric variables was
observed following up titration of medication.
Conclusion: In stable patients with HF airflow obstruction is frequent and severely underdiagnosed. Spirometry
should be considered in all patients with HF in order to improve diagnosis and treatment for concomitant
pulmonary disease.
Keywords: COPD, Heart failure, Spirometry
Background
In patients with HF, chronic obstructive pulmonary
disease (COPD) is an important differential or additional
diagnosis due to sharing of risk factors (smoking) and
symptoms (dyspnoea and fatigue). Diagnosing COPD in
patients with HF is essential both because dyspnoea in
patients with both diseases presents a particular chal-
lenge and because the combination of COPD and HF
identifies a high-risk population [1–4]. Furthermore can
a normal spirometric examination rule-out the coexist-
ence of COPD and other lung disease which might avoid
the use of unnecessary medication and help the clinician
in focusing on the heart disease [5]. Studies of patients
with HF have shown a prevalence of self-reported COPD
of 10–33% [1, 3, 6] and studies of spirometry in patients
with HF have shown an even higher prevalence of
COPD (30–39%). However, most of these studies were
either small [7, 8] or performed on patients with acute
HF [9]. Recently, two larger studies suggest that spirom-
etry might overestimate the presence of COPD in patients
with heart failure and that the dynamic nature of lung
function makes serial assessment mandatory [10, 11]. Pre-
vious studies of patients with HF have shown that acute
and chronic congestion can lead to some reduction in
lung function, and that treatment of congestion can partly
reverse this [12, 13].
The purpose of the present study was to determine
the prevalence of airflow obstruction in stable patients
with HF and to examine the effect of optimal medical
treatment for HF on lung function parameters.* Correspondence: md@dadlnet.dk1Department of Cardiology, Herlev Hospital, Copenhagen University Hospital,
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All patients referred to 10 different Danish HF clinics
for medical optimization between 1 January 2009 and 1
November 2011 were screened for inclusion in the
study. Patients in the HF clinics were referred from gen-
eral practitioners or other departments at the hospital.
All patients with functional impairment corresponding
to New York Heart Association (NYHA) functional class
II-IV and with left ventricular ejection fraction (LVEF) <
45% were eligible for the study. Echocardiography was
performed, by the referring departments or the hospital
outpatient clinics, prior to inclusion in the study. Stable
outpatients were examined with spirometry at the first
visit to the HF clinic and again at the last visit where
maximal possible doses of HF medication were achieved
and patients were referred to further follow up by their
general practitioner.
Demographic data and medical history
Baseline demographic data, data on the use of tobacco,
standard blood tests (creatinine, hemoglobin, sodium
and potassium), previous medical history and the reason
for development of HF were registered. At baseline and
at the last visit doses and types of HF medication were
registered. Doses of HF medications are in the following
reported as % of doses recommended in the recent
European guideline for betablockers and inhibitors of
the renin angiotensine system [14].
Spirometry
Forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) were measured (Micro Medical Micro-
Lab 3300) in a seated position without prior administra-
tion of a bronchodilator. At least three acceptable
spirometric measurements were taken and the highest
values were used. Measurements with a variation of
FEV1 of up to 10% of the two highest recordings were
accepted. Trained study nurses performed spirometry.
Two investigators (KKI and MD) reviewed all the
spirometry tracings and excluded those with signs of
sub-optimal performance. The international recommen-
dations were used to calculate predicted values [15] and
in the following FEV1 and FVC are given as the percent-
ages of these values. airflow obstruction was diagnosed
according to GOLD criteria as an FEV1/FVC ratio < 0.7,
and the degree of airflow impairment was graded ac-
cording to the GOLD 2011 revision [16]. Mild airflow
obstruction was defined as FEV1 ≥ 80% of predicted
(GOLD I), moderate as FEV1 < 80% and ≥ 50% of
predicted (GOLD II), severe as FEV1 < 50% and ≥ 30% of
predicted (GOLD III) and very severe if FEV1 < 30% pre-
dicted (GOLD IV).
As a supplement to the GOLD criteria for defining air-
flow obstruction, the Lower Limit of Normality (LLN)
criteria were used to analyse our data for comparative
purposes. airflow obstruction is defined as having a
FEV1/FVC ratio below the lower limit of normal, which
is defined as the lower 5th percentile of a healthy popula-
tion as recommended by the American Thoracic Society
and European Respiratory Community [17]. We used
reference values from a large Danish study as baseline
for the calculations of the FEV1/FVC ratio [18]. Patients
with a spirometry with FEV1/FVC ≥ 0.7 and FVC < 80%
of expected was defined as lung function impairment
with a non-obstructive pattern/reserved ratio with im-
paired spirometry.
Statistics
Comparisons between data in categories were performed
using the chi-squared test, comparisons between con-
tinuous data using the Student’s t-test and comparisons
between baseline and follow-up using the paired t-test.
Multivariable analysis of variables associated with the
presence of airflow obstruction was performed using logis-
tic regression analysis with backward elimination (p = 0.1
as threshold for inclusion in the model).
Sensitivity, specificity, positive and negative predictive
values were calculated with standard methods. All confi-
dence intervals were constructed to have coverage of
95% and a p-value < 0.05 was considered significant.
Statistical calculations were performed with SPSS soft-
ware, version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Characterization of the patients
Screening was performed on 691 patients referred to the
HF clinics. Of these 590 (85%) were included in the study.
The main reasons for non-inclusion were patients inability
to perform a spirometry of sufficient quality or patients
not willing to participate in the study. Of the included
patients 335 (57%) performed a follow-up spirometry, the
main reason for missing follow-up spirometry was that
the patients were terminated from follow-up earlier than
expected from the HF outpatient clinic (due to death,
severe comorbidity or the patient’s own decision).
Twentyfour % of the patients were active smokers and
50% were previous smokers. Baseline characteristics for
included and not included patients appear from Table 1.
Patients not included were more often women, had
lower NYHA-class and lower blood pressure than
included patients. Apart from a slightly difference in
sodium there were no difference between patients that
did not complete follow-up and patients that completed
the follow-up.
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Spirometric findings
At baseline mean FEV1 was 78% of expected (95% confi-
dence interval 77–80%), mean FVC was 86% of expected
(84–87%) and mean FEV1/FVC was 0.72 (0.71–0.72), data
are presented in Fig. 1. Airflow obstruction (according to
GOLD criteria) was present in 228 patients (38%) of
which 51 (9%) were in GOLD grade of airflow obstruction
I, 137 (23%) were in GOLD grade of airflow obstruction
II, 38 (6%) were in GOLD grade of airflow obstruction III
and 2 (0.3%) were in GOLD grade of airflow obstruction
IV. A logistic regression was performed including all vari-
ables from Table 1. The only variables that independently
predicted the presence of airflow obstruction were BMI,
OR = 0.94 per increase in BMI of 1 kg/m2, (0.89–0.99),
previous smoking, OR = 2.7 (1.0–7.3) and age 1.04 per
year (1.01–1.08). Among present or previous smokers 43%
of patients had an obstructive pattern while 24% of never
smokers had an obstructive lung function impairment (p
< 0.001). Furthermore were 34/35 (97%) of never smokers
in GOLD grade of airflow obstruction 1 or 2 compared to
147/184 (80% of present or previous smokers (p < 0.001).
Furthermore, 130 (22%) had a lung function impair-
ment with a non-obstructive pattern/ preserved ratio
with impaired spirometry (i.e., FEV1/FVC ≥ 0.7 and FVC
< 80% of expected), leaving 39% of the patients having a
normal lung function.
Association between spirometric findings and medical
history
According to the patient records and the patients’ own in-
formation, 71 (12%) of the patients had previously been
diagnosed with COPD (information of self-reported
COPD was available in 582 (99%) of the patients). The as-
sociation between airflow obstruction based on spirometry
and self-reported COPD is presented in Table 2. Even
though airflow obstruction based on spirometry was more
frequent in patients with self-reported COPD (p < 0.01),
35% of the patients without known COPD had airflow ob-
struction. On the other hand 34% of the patients with self-
reported COPD had no obstructive airflow obstruction
(60% had normal spirometry and 40% had a restrictive
pattern). Of the 228 patients with airflow obstruction only
47 (21%) had previously been diagnosed with COPD. The
sensitivity of self-reported COPD compared to airflow
obstruction based on spirometry was 0.21 (0.16–0.27),
specificity was 0.93 (0.91–0.96), the positive predictive
value was 0.66 (0.53–0.76) and the negative predictive
value was 0.65 (0.61–0.69). Using logistic regression
including variables from Table 1, BMI, OR = 0.94 per
kg/m2, (0.89–0.99), previous smoking, OR = 2.7 (1.0–
7.3) and age 1.04 per year (1.01–1.08) independently
predicted the presence of obstructive lung function
impairment.
Table 1 Baseline characteristics for included and not included patients
Included P-value Not included P-value




FU/no FU (n = 101) Included/not included
Age years (SD) 69 (11) 68 (12) 0.61 71 (12) 0.59
Female gender n(%) 89 (27%) 67 (26%) 0.95 36 (36%) 0.04
NYHA III-IV n(%) 74 (25%) 61 (27%) 0.50 20 (20%) 0.03
Known COPD n(%) 44 (13%) 27 (11%) 0.27 12 (12%) 0.52
Previous or present smoking n(%) 238 (72%) 189 (78%) 0.14 73 (77%) 0.70
Body mass index kg/m2 (SD) 27 (5) 27 (5) 0.50 27 (6) 0.46
Systolic blood pressure mmHg (SD) 130 (22) 130 (25) 0.59 119 (22) <0.01
Diastolic blood pressure mmHg (SD) 77 (13) 76 (11) 0.82 69 (15) <0.01
Heart rate/minute (SD) 74 (15) 75 (14) 0.56 74 (13) 0.98
Ejection fraction % (SD) 31 (9) 31 (9) 0.46 31 (9) 0.52
eGFR’ ml/min (SD) 85 (124) 76 (102) 0.63 82 (118) 0.79
Sodium mmol/l (SD) 138 (4) 137 (4) 0.02 139 (1.4) 0.54
Potassium mmol/l (SD) 4.2 (0.5) 4.2 (0.5) 0.69 4.1 (0.4) 0.61
Treated with ACEI/ARB n(%) 308 (92%) 233 (92%) 0.89 87 (86%) 0.21
Treated with β-blocker n(%) 259 (77%) 197 (80%) 0.48 67 (66%) 0.31
Treated with loop-diuretics n(%) 200 (60%) 150 (61%) 0.88 53 (52%) 0.38
Treated with thiazides n(%) 29 (9%) 18 (7%) 0.26 10 (10%) 0.57
Treated with spironolactone n(%) 59 (18%) 53 (21%) 0.29 26 (26%) 0.06
‘estimated glomerular filtration rate
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Comparison between LLN and GOLD criterias for airflow
obstruction
Using LLN instead of GOLD criteria reduced the num-
ber of patients with airflow obstruction from 228 (38%)
to 176 (30%) (p < 0.01). Comparing these criteria’s with
self-reported COPD showed that 26% of the patients
without known COPD had airflow obstruction and that
39% of the patients with known COPD did not have any
airflow obstruction. The sensitivity of self-reported COPD
compared to airflow obstruction based on spirometry
using the LLN criteria was 0.24 (0.17–0.33), specificity
was 0.93 (0.91–0.95), the positive predictive value was
0.61 (0.48–0.72) and the negative predictive value was
0.74 (0.70–0.78).
Change in spirometry after medical uptitration in HF
medication
Data on the 335 patients who completed the follow-up
is presented in Table 3. Median time between baseline
and follow-up was 174 days (inter quartile range 98–282).
Blood pressure and heart rate were reduced, fewer pa-
tients were in NYHA class III and IV, and doses of ACE-
inhibitors, beta-blockers and spironolactone increased
during follow-up. In the entire population, mean values of
FEV1, FVC and FEV1/FVC did not change significantly
from baseline to follow-up. Values for FEV1 changed from
77.6% of expected to 76.4% of expected, p = 0.11; FVC
from 84.9% of expected to 84.0% of expected, p = 0.27 and
FEV1/FVC from 0.72 to 0.71, p = 0.22. In Fig. 2 Bland-
Altman plots illustrate the change in FEV1, FVC and
FEV1/FVC from follow-up to baseline as a function of the
average values. It appears from the figure that lung func-
tion was stable over time and that any variability seems
independent of level of lung function . Of the patients
with airflow obstruction (FEV1/FVC < 0.7) at baseline 29
(12.7%) did not have airflow obstruction at follow-up,
whereas 39 (10.8%) of the patients with no airflow ob-
struction at baseline had airflow obstruction at follow-up.
Sensitivity of self-reported COPD compared to airflow
obstructionbased on follow-up spirometry was 0.25 (0.18–
0.33) and specificity was 0.95 (0.90–0.95), which not was
different to results from the baseline spirometry (p > 0.05)
Discussion
In a stable outpatient HF population more than one
third of the patients had airflow obstruction and 78% of
Fig. 1 Histograms of spirometric variables (panel a; FEV1 in
percentage of expected, panel b; FVC in percentage of expected,
panel c; FEV1 /FVC)
Table 2 The association between COPD based on spirometry and self-reported COPD
No obstructive airflow obstruction Obstructive airflow obstruction
GOLD grade of airflow obstruction
Self-reported COPD I II III IV
Absent n (%) 333 (65%) 50 (10%) 107 (21%) 20 (4%) 1 (0.2%)
Present n (%) 24 (34%) 1 (1%) 27 (38%) 18 (25%) 1 (1%)
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the patients had at least moderate to severe airflow ob-
struction (GOLD II-IV). Of these, only one in five had
previously been diagnosed with COPD.. Even though the
stable patients might have a degree of chronic conges-
tion at baseline that is reduced after optimization of
specific treatment for HF lung function parameters did
not change. This suggests that congestion only plays a
minor role in the observed lung function impairment.
The prevalence of lung disease in patients with HF has
previously primarily been described using self-reported
COPD [1, 3, 6, 19]. The prevalence of COPD in these
studies has varied between 10–33%. Only a handful of
studies have examined patients with HF with spirometry.
The findings are, however, relatively consistent, with
approximately one third of the patients having airflow
obstruction based on spirometry. One of the largest
studies included 527 patients, but the study population
consisted of patients admitted with acute HF, and con-
gestion could therefore potentially have lead to overesti-
mation of the lung function impairment [9]. Recently,
two similar sized studies have shown that the airflow ob-
struction observed in patients with HF is dynamic and
that serial measurements is mandatory to minimize the
risk of false positive COPD diagnoses [10, 11]. The four
minor studies were all in smaller and/or selected popula-
tions (118–187 patients) [7, 8, 20, 21]. None of the stud-
ies have performed serial spirometry and only one study
used cut-off values for FEV1/FVC other than a fixed
value of 0.7, which might overestimate the prevalence of
airflow obstruction in an older population [7, 22].
The primary strength of the present study is that it is
the largest study examining serial lung function in
stable patients with HF. Furthermore, is this the only
larger study that uses both LLN and GOLD criteria in
the airflow obstruction diagnosis. Only 85% of the
screening population was included in the study and
follow-up was only possible in 57% of the included pa-
tients. However, only minor differences in baseline vari-
ables were observed between included and not included
patients, which reduce the risk for selection bias.
Furthermore follow-up was only possible in 57% of the
patients. Nurses in the HF clinic performed the spirom-
etry. Theses nurses had prior to the study only limited
experience in performing spirometry. However, all
nurses were prior to the study trained in spirometry
and furthermore two experienced investigators (KI and
MD) reviewed and approved all tracings prior to inclu-
sion of the data in the study. The prevalence of undiag-
nosed asthma in this study is unknown and potentially
some of the patients with airflow obstruction could
have asthma and not COPD. A previous study of re-
versibility of airflow obstruction in patients with HF did
not find any effect of an inhaled bronchodilator [9] and
the risk of undiagnosed asthma in this rather old popu-
lation is probably verylow. This is a screening study
and the airflow obstruction diagnosis is solely based on
spirometry, caution is therefore warranted when inter-
preting the prevalence of airflow obstruction in this
study. The relatively high percentage of airflow obstruc-
tion in never smokers also underlines that an obstruct-
ive pattern not necessarily means that the patient has
COPD in this study. Knowledge about smoking history
is central in interpretation of a spirometry and the
study would therefore have been strengthened by fur-
ther knowledge of smoking history. Almost 13% of the
patients with airflow obstruction at baseline did not
have airflow obstruction at follow-up. These patients
had only minor airflow obstruction and the changes
were below 10%. The explanations for this finding
might be several and include that some patients had
asthma, some had minor congestion, and maybe most
likely biological and examiner variability.
Table 3 Data on the 335 patients who completed the follow-up
Baseline Follow-up P
NYHA III-IV n(%) 74 (22%) 33 (10%) <0.01
Weight, kg (SD) 82 (19) 82 (20) 0.39
Systolic blood pressure, mmHg (SD) 129 (20) 124 (21) <0.01
Diastolic blood pressure, mmHg (SD) 77 (14) 74 (11) 0.01
Heart rate, /minute (SD) 74 (15) 67 (13) <0.01
ACE-inhibitor, % of recommended dose (SD) 46 (35) 68 (42) <0.01
Beta-blocker, % of recommended dose (SD) 32 (30) 63 (38) <0.01
Dose of furosemide, mg (SD) 61 (108) 56 (107) 0.03
Treated with spironolactone, n(%) 58 (18%) 73 (22%) 0.01
FEV1, % of expected (SD) 77 (19) 76 (22) 0.11
FVC, % of expected (SD) 85 (18) 84 (21) 0.27
FEV1/FVC, (SD) 0.72 (0.10) 0.71 (0.11) 0.22
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Over-diagnosis of COPD might be as important a clin-
ical issue as under-diagnosis. This is partly due a poten-
tial overuse of medication for COPD and partly due to
the possibility that clinicians think that dyspnoe is due
to lung disease instead of heart disease. The use of the
LLN criteria instead of a fixed ratio has been suggested
to reduce the problem with over-diagnosis. Previous
studies have shown that the number of patients with air-
way obstruction is reduced with approximately one third
if LLN is used instead of a fixed ratio [23]. A small study
has examined this issue in a population of heart failure
patients (n = 89) [24]. They found a reduction of nearly
50% of the number of patients with air way obstruction
if LLN is used. In the present study we found a signifi-
cant, but minor than previously reported, difference
between LLN and fixed ratio diagnoses of airway ob-
struction. This finding suggests that over-diagnosis of
COPD in HF patients with the use of criteria based on a
fixed ratio might be less than previously thought. On the
other hand, the minor differences between earlier studies
and this study might at least in part be due to difference
in age of patients included in the studies as the differ-
ence between LLN and fixed ratio for diagnosing airflow
obstruction is age dependent. The reason for the high
coexistence of airflow obstruction and HF is probably
multifactorial. The sharing of the common risk factor -
smoking - is one important factor. However, it has
recently been proposed that low-grade inflammation
observed in COPD could be a link between the two dis-
eases [25–29]. The role of congestion on pulmonary
function has been debated and results from previous
studies are conflicting. Acute saline infusion in patients
with HF has been shown to increase airflow obstruction
but not to induce restriction [30]. Similarly, studies in
patients with mitral valve stenosis have shown that bron-
chial hyperreactivity was associated with increased filling
pressures of the left ventricle [12]. In contrast, other
studies have shown that FVC and not FEV1 were related
to degree of congestion in heart failure patients [13, 31],
and that heart transplantation normalized the restriction
in the majority of patients [31]. Still, most studies show
that both FEV1 and FVC are correlated to congestion
and that medical treatment or surgery that alleviates
congestion improves both parameters [32–36]. In the
present study, optimal treatment of HF changed neither
FEV1 nor FVC. This could at least partly be explained by
patients already being stable at baseline and that the
level of congestion therefore probably was minimal. The
lack of change in body weight from baseline to follow-
up supports this notion.
In this study we found that almost one fourth of the
patients had a lung function impairment with a non-
obstructive pattern. Treatment of this condition can be
difficult and therefore might the clinical relevance of this
finding be limited. While some of the patients might
have an impaired lung function du to non-pulmonary
causes (adipositas or chronic congestion) some of the
patients could potentially have severe primary lung dis-
ease (i.e., pulmonary fibrosis). The relevance of this find-
ing should therefore be investigated in future studies.
We could confirm previous findings of a very low agree-
ment rate between self-reported COPD and airflow obstruc-
tion diagnosed by spirometry. The sharing of symptoms –
Fig. 2 Bland-Altman plot of the difference in spirometric variables
after and before up-titration of HF medication (panel a; FEV1, panel
b; FVC, panel c; FEV1 /FVC)
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dyspnoea - implicates that there are significant diagnostic
challenges between HF and COPD. Both auscultation [37]
and history [23] is difficult to use for differentiation between
heart disease and lung disease and even though natriuretic
peptides can diagnose HF, they can not exclude pulmonary
disease. Diagnosing and treating undiagnosed COPD might
be essential in patients with HF as a growing level of evi-
dence has shown that targeted treatment for COPD reduces
symptoms, improves quality of life and may improve prog-
nosis [38]. Furthermore, the knowledge of patients having
COPD may reduce the risk of overdosing diuretics due to
misinterpretation of the background for patients having
dyspnoea. It therefore seems relevant to perform spirometry
– a simple, cost-effective, non-invasive and objective exam-
ination – in all patients with HF.
Conclusion
In stable patients with HF airflow obstruction is frequent
and severely underdiagnosed. Spirometry should be con-
sidered in all patients with HF in order to improve diag-
nosis and treatment for concomitant pulmonary disease.
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